English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 expressing neuroendocrine tumors,' will be delivered by Dr. Richard L. Wahl on November 22, 2024. The company will host a conference call on November 21 to discuss the data, featuring Dr. Wahl and including a Q&A session.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
7676 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    8975
    Followers
    54
    Following
    106K
    Visitors
    Follow
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.